Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, provided a corporate update and reported financial results for the first quarter ended March 31, 2020.
May 11, 2020
· 8 min read